NasdaqCM - Delayed Quote • USD
aTyr Pharma, Inc. (LIFE)
At close: 4:00 PM EDT
After hours: 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 4 |
| Avg. Estimate | -0.24 | -0.24 | -0.94 | -0.95 |
| Low Estimate | -0.29 | -0.3 | -1.19 | -1.11 |
| High Estimate | -0.18 | -0.19 | -0.75 | -0.64 |
| Year Ago EPS | -0.29 | -0.22 | -0.94 | -0.94 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 4 |
| Avg. Estimate | 20k | 20k | 2.16M | 9.26M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 100k | 100k | 10M | 24.43M |
| Year Ago Sales | 300k | -- | 353k | 2.16M |
| Sales Growth (year/est) | -93.30% | -- | 511.90% | 328.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.4 | -0.28 | -0.23 | -0.24 |
| EPS Actual | -0.29 | -0.22 | -0.2 | -0.25 |
| Difference | 0.11 | 0.06 | 0.03 | -0.01 |
| Surprise % | 27.50% | 21.40% | 13.00% | -4.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.24 | -0.24 | -0.94 | -0.95 |
| 7 Days Ago | -0.24 | -0.24 | -0.94 | -0.95 |
| 30 Days Ago | -0.24 | -0.24 | -0.94 | -0.95 |
| 60 Days Ago | -0.21 | -0.21 | -0.85 | -0.95 |
| 90 Days Ago | -0.21 | -0.21 | -0.85 | -0.95 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | LIFE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 17.20% | -- | -- | 6.50% |
| Next Qtr. | -9.10% | -- | -- | 12.00% |
| Current Year | 0.00% | -- | -- | 5.30% |
| Next Year | -1.10% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 13.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | RBC Capital: Outperform to Outperform | 3/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/21/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/21/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/14/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/10/2023 |
Related Tickers
MREO Mereo BioPharma Group plc
2.7400
-2.49%
SCPH scPharmaceuticals Inc.
4.4900
+3.22%
KZR Kezar Life Sciences, Inc.
0.8049
+1.89%
MDNAF Medicenna Therapeutics Corp.
1.8200
+30.00%
LPTX Leap Therapeutics, Inc.
3.2500
+2.52%
RLMD Relmada Therapeutics, Inc.
3.8300
+3.51%
CNSP CNS Pharmaceuticals, Inc.
0.2150
+2.87%
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
GLYC GlycoMimetics, Inc.
1.6400
-4.09%
MIST Milestone Pharmaceuticals Inc.
1.5400
-3.14%